Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhino ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP), a ...

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

CompanyOverview|NASDAQ:REGN] Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major ...